Ariad Pharmaceuticals Inc (NASDAQ:ARIA) is set to announce its Q114 earnings results on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $11.12 million for the quarter. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.45 moved to $7.73 on last trade day and at the end of the day closed at $7.63 . Company price to sales ratio in past twelve months was calculated as 31.26 and price to cash ratio as 6.01. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 9.00%.
Galena Biopharma Inc (NASDAQ:GALE) has reported that it would be releasing the results of the first quarter of 2014 soon. The company would also host a conference call in order to discuss these results, Galena Biopharma reported. The CEO if Galena Biopharma would be giving a presentation at a health care conference. Galena Biopharma has also recently reported that a pioneer of the company had won an award in technology transfer for excellence. Galena Biopharma Inc (NASDAQ:GALE) shares advanced 8.20% in last trading session and ended the day on $2.64. GALE return on equity ratio is recorded as -435.40% and its return on assets is -113.60%. Galena Biopharma Inc (NASDAQ:GALE) yearly performance is 6.45%.
XOMA Corp (NASDAQ:XOMA) a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, May 7, 2014, at 4:30 p.m. Eastern time to discuss first quarter 2014 financial results and provide an update on gevokizumab’s global clinical programs. XOMA Corp (NASDAQ:XOMA) shares moved up 8.14% in last trading session and was closed at $ 4.65 while trading in range of $4.20 -$4.69 – XOMA Corp (NASDAQ:XOMA) year to date (YTD) performance is -30.91%.
Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, tell in detail the topline Phase II study results of Trimesta™ (oral estriol), which the Company is developing as a once-daily adjunctive oral treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Topline data were announced yesterday by the University of California, Los Angeles (UCLA) School of Medicine and presented at the 66th Annual Meeting of the American Academy of Neurology by the study’s lead investigator, Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA David Geffen School of Medicine. Synthetic Biologics Inc (NYSEMKT:SYN) weekly performance is -51.20%. On last trading day company shares ended up $1.42. Synthetic Biologics Inc (NYSEMKT:SYN) distance from 50-day simple moving average (SMA50) is -46.84%. Analysts mean target price for the company is $3.95.
Leave a Reply